<DOC>
	<DOCNO>NCT02681614</DOCNO>
	<brief_summary>This clinical research study test Uronav system . Patients prostate cancer ask take part study . Uronav system investigational device use study help place marker patient . These call fiducial marker place patient help plan radiation treatment . Radiation therapy treatment plan treat physician experimental part research study . This study also test similarity difference biopsy tissue structure finding intraprostatic MRI ( internally guide MRI ) .</brief_summary>
	<brief_title>Pilot Study Evaluating Role Histopathology Correlation Treatment Planning</brief_title>
	<detailed_description>Study Objectives Specific Aim 1 : Evaluate final pathology post-operatively histopathology confirmation multiparametric MRI target detect treatment planning . This accomplish use transperineal biopsy obtain prior interstitial brachytherapy procedure , anesthetic prior placement brachytherapy needle source . Specific Aim 2 : Evaluate ability Uronav system transperineal set guide biopsy needle placement use electromagnetic guidance system transperineal ultrasound probe stabilization device stepper .</detailed_description>
	<criteria>Patients must histopathology confirmed prostate cancer Gleason score ≤7 ( 4+3 ) clinical stage ≤ T2bN0M0 Prostatespecific antigen ( PSA ) 15 ng/mL . Patients must MRI finding report intraprostatic lesion suspicious malignancy . Patient must prior treatment include hormonal therapy , radiotherapy , surgery Eastern Cooperative Oncology Group ( ECOG ) Performance status ≤ 2 Subjects must International Prostate Symptom Score ≤ 15 . Subjects must ability understand willingness sign write informed consent document . Gleason score ≥ 8 ( 4+4 ) PSA ≥ 15 ng/mL . Clinical stage &gt; T2b evidence nodal Patients anticoagulant high dose aspirin therapy safely stop great 10 day prior treatment exclude limit increase risk urinary obstruction . Patients uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . HIVpositive patient combination antiretroviral therapy ineligible unlikely risk prostate cancer life threaten population .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Imaging</keyword>
	<keyword>Prostate</keyword>
	<keyword>Multiparametric MRI</keyword>
	<keyword>brachytherapy</keyword>
</DOC>